Cantargia (CANTA) investor relations material

Executive summary

• Raised SEK 132 million through rights issue and loan facility to support clinical priorities, including nadunolimab studies in PDAC and hematologic malignancies.

• All evaluable high-risk MDS patients in the Phase I-B/II-A trial achieved complete remission, with ongoing expansion at MD Anderson.

• Advanced IL1RAP antibody platform with new investigator-initiated studies, published data validating IL1RAP in PDAC, and expanded pipeline including CAN14 and CANxx.

• Strategic partnership with Otsuka for CAN10 continues, providing milestone and royalty potential.

Financial highlights

• Q2 2026 revenues: SEK 0.1 million; operating expenses: SEK 35.9 million; net loss: SEK 32.8 million; EPS: -0.13 SEK.

• H1 2026 revenues: SEK 0.6 million; operating expenses: SEK 73.3 million; net loss: SEK 65.8 million; EPS: -0.26 SEK.

• Operating expenses decreased 9% year-over-year in Q2 and 13% in H1, mainly due to lower R&D and CAN10 divestment.

• Available funds as of June 30, 2026: SEK 222 million, up from SEK 82 million in 2025.

• Cash runway, including new proceeds, expected to fund operations through mid-2028.

Outlook and guidance

• Planned Phase I-B study of nadunolimab with daraxonrasib in second-line PDAC to start in Q1 2027, subject to regulatory approval and drug availability.

• Expansion of Phase I-B/II-A trial in hematologic malignancies at MD Anderson is funded and ongoing.

• Interim data from the hematology study may be disclosed at ASH 2026, pending abstract acceptance.

• R&D spending expected to ramp up in H2 2026 and into 2027 as new studies initiate.

• No milestone payments from collaborations expected in 2026; future revenues depend on CAN10 development and royalties.